

1 **Differential effect of corticosteroid treatment on Influenza, SARS, MERS, and**
2 **SARS-CoV-2 patients: A meta-analysis and systematic review**

3 **Authors:** Sobur Ali^{1a}, Salman Zahir Uddin^{1a}, Md. Nayem Dewan², M Moniruzzaman¹, Mir
4 Himayet Kabir³, Mohammad Rafiqul Islam⁴, Hossain Monir¹, Shanewaz Hossain⁵, Tanvir Noor
5 Nafiz¹, Rumana Rashid⁶, Khan Mohammad Imran^{7*}

6 **Address:** a. Equal contribution

- 7 1. Department of Microbiology, University of Dhaka, Dhaka-1000, Bangladesh
8 2. Institute of Statistical Research and Training, University of Dhaka, Dhaka-1000, Bangladesh
9 3. Department of Medical Microbiology and Immunology, School of Medicine and Life Science,
10 University of Toledo, 2801 Bancroft St, Toledo, OH 43606
11 4. Department of Chemistry, Jahangirnagar University, Savar, Dhaka, Bangladesh
12 5. Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh
13 6. Economics Discipline, Social Science School, Khulna University, Khulna, Bangladesh
14 7. Graduate Program in Translational Biology, Medicine, and Health, Virginia Tech, Blacksburg,
15 VA 24061

16 Running title: Variable effect of corticosteroid

17 ***Corresponding Author:**

18 Khan Mohammad Imran

19 Room 126, 295 Duck Pond Drive, Virginia Tech, Blacksburg, VA 24061

20 email-imrankhan@vt.edu

21 Contact no. +1(540)-998-9437

22

23

24 **ABSTRACT**

25 **Background:** Corticosteroid has been used to manage inflammation caused by many diseases
26 including respiratory viral infections. Many articles are available to support the good and bad
27 side of this steroid use but remain inconclusive. To find some evidence about the safety of the
28 drug, we investigated the effect of corticosteroids on the mortality of patients with respiratory
29 viral infections including SARS-CoV-2, SARS, MERS, and Influenza.

30 **Method:** We searched articles in PubMed, Scopus, Cochrane, Medline, Google Scholar, and
31 Web of Science records using keywords “corticosteroid” or “viral infection” or “patients” or
32 “control study”. Mortality was the primary outcome.

33 **Result:** Our selected 24 studies involving 16633 patients were pooled in our meta-analysis.
34 Corticosteroid use and overall mortality were not significantly associated ($P=0.176$), but in
35 subgroup analysis, corticosteroid use was significantly associated with lower mortality in the
36 case of SARS ($P=0.003$) but was not significantly associated with mortality for Influenza
37 (H1N1) ($P=0.260$) and SARS-CoV-2 ($P=0.554$). Further analysis using study types of SARS-
38 CoV-2, we found that corticosteroid use was not significantly associated with mortality in the
39 case of retrospective cohort studies ($P=0.256$) but was significantly associated with lower
40 mortality in the case of randomized control trials ($P=0.005$). Our findings uncover how the
41 outcome of particular drug treatment for different diseases with comparable pathogenesis may
42 not be similar and, RCTs are sometimes required for robust outcome data.

43 **Conclusion:** At the beginning of the COVID-19 pandemic, data of corticosteroid use from other
44 viral infections along with COVID-19 observational and retrospective cohort studies created
45 confusion of its effect, but randomized control trials showed that corticosteroid can be used to
46 treat COVID-19 patients.

- 47 **Keywords:** Meta-analysis, systematic reviews, COVID-19, corticosteroids, SARS, MERS,
48 H1N1 influenza

49 **1. Introduction**

50 *1.1 Respiratory Virus*

51 Respiratory infections represent the leading cause of disease and economic burden [1]. They are
52 linked with a number of clinical symptoms from upper respiratory tract self-limited infections to
53 more severe conditions in the lower respiratory tract, for example, pneumonia. Respiratory
54 viruses (RVs) includes but are not limited to influenza virus, adenovirus, human coronavirus,
55 human metapneumovirus, rhinovirus (RV), parainfluenza, and respiratory syncytial virus (RSV),
56 may cause severe diseases such as pneumonia and bronchiolitis and/or exacerbate chronic
57 obstructive pulmonary disease (COPD) and asthma. Moreover, the Avian influenza virus
58 (H5N1), SARS coronavirus (SARS-CoV), and MARS coronavirus (MARS-CoV) have emerged
59 in recent years as potential threats to the public health attracting global attention. The
60 coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome
61 coronavirus 2 (SARS-CoV-2) originating in Wuhan, China, is swiftly and continuously
62 spreading globally and responsible for significant respiratory morbidity and mortality [2].

63 *1.2 Corticosteroid*

64 Corticosteroids, often known as steroids, are classes of hormones secreted by the adrenal cortex,
65 including glucocorticoids (GCs) and mineralocorticoids [3]. Nevertheless, the term
66 "corticosteroids" is commonly used to denote glucocorticoids. Corticosteroids control various
67 cellular functions such as metabolism, development, cognition, inflammation, and homeostasis
68 [4]. Corticosteroids are being used regularly in clinics to treat autoimmune and inflammatory
69 pathologies such as allergy, septic shock, asthma, rheumatoid arthritis, multiple sclerosis, and
70 inflammatory bowel disease. The adverse effects of prolonged glucocorticoid therapy are well

71 established and exceedingly common which limits the therapeutic benefits. Some side effects of
72 certain medical conditions after taking corticosteroid are glucose intolerance and diabetes,
73 osteoporosis and fracture, muscle wasting, central obesity, growth retardation, depression,
74 hypertension cataracts, and increased risk of viral and bacterial infections [5].

75 To the current day, nevertheless, corticosteroids continue to be the backbone in the treatment of
76 autoimmune disorders and inflammatory diseases, and they are prescribed as an
77 immunosuppressant after organ transplantation and as lymphocytic in chemotherapeutic
78 treatments [6].

79 *1.3 Corticosteroid and immunosuppression*

80 Corticosteroids, especially glucocorticosteroids, have inhibitory properties on a wide range of
81 immune responses [7]. They are steroid hormones with extensive effects. They often exert anti-
82 inflammatory and potent immune-suppressive effects when pharmacologically driven. These are
83 typically used to prevent the harmful effects of the inflammatory cascades in severe infections
84 [8] and that's why they are used to treat inflammatory diseases due to the inhibition of B cells
85 and T cells mediated immune responses [7]. To date, the immunomodulatory function of
86 glucocorticoid analogs has been difficult to discern from their untoward effects, which reflects
87 the fact that most of the activities of cortisol are regulated by a particular molecule of the nuclear
88 receptors. For the future production of more active immunosuppressive agents, a better
89 comprehension of the molecular base of steroids on the immune response is thus necessary [9].

90 While glucocorticoids play a role in stimulating lymphocyte apoptosis and in altering leukocyte
91 movement and redistribution, the key component of their action is the suppression of cytokine

92 gene expression, resulting in a reduced release of interferons (IFN- α), interleukins (IL-2, IL-6),
93 and tumor necrosis factor (TNF- α) [9].

94 *1.4 Use of corticosteroid in respiratory viral infection*

95 Even after controversy, it is a very common trend to administer corticosteroids to influenza
96 patients, especially pandemic influenza virus. The use of corticosteroids increases the chance of
97 infection by various microorganisms and it is significantly associated with mortality (OR 1.98,
98 95% CI 1.62-2.43, $p < 0.00001$) and nosocomial infection (OR 3.16, 95% CI 2.09-4.78, $p <$
99 0.00001) [10]. Patients with pandemic H1N1 viral infection whose rapidly deteriorating
100 pneumonia leads to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) along
101 with several organ dysfunctions were found associated with an increased rate of mortality (14–
102 41%) [11]. In clinical practice, the application of adjuvant corticosteroid treatment of those
103 patients is very common. Other studies have shown that systemic corticosteroid therapy may
104 inhibit the inflammatory cascade reaction in patients with community-acquired pneumonia [12].
105 It has also been reported that corticosteroid use was not significantly associated with 90-day
106 mortality (adjusted odds ratio, 0.75; 95% confidence interval, 0.52-1.07; $P=0.12$) but found to be
107 associated with the delay in RNA clearance of MERS coronavirus (adjusted hazard ratio, 0.35;
108 95% CI, 0.17-0.72; $P=0.005$) [13].

109 *1.5 Covid-19 and corticosteroid*

110 To date, 115 million people are infected by the SARS-CoV-2 virus worldwide and caused 2.5
111 million death [14]. Although vaccination has been started, only 269 million out of 7.79 billion
112 have been given a single shot and 56 million people have been fully vaccinated (0.72% of the
113 total population) [15].

114 The complex condition of severely ailing patients with COVID-19 leads to an array of protocols
115 employing complementary treatments including the use of corticosteroids for the treatment of
116 phase IIb-III COVID-19 patients in hospital[16–18]. The vital point is that corticosteroids might
117 be useful in checking cytokine and chemokine storm-mediated alveolar/pulmonary damage. In
118 this condition, corticosteroids are used as immunosuppressants (inhibition of cytokine
119 production) resulting in impaired lymphocyte proliferation and delay in the clearance of the virus
120 [17,19]. Nevertheless, there are several studies reported the use of corticosteroids for the
121 management of ARDS caused by several severe coronavirus infections such as severe acute
122 respiratory syndrome (SARS) [20] and the Middle East respiratory syndrome (MERS) [13]
123 where diffused alveolar damage and histological pulmonary inflammation are common [21].

124 Patients with COVID-19 are frequently treated with corticosteroids regardless of the deficiency
125 of effectiveness evidence from clinical studies [22]. Moreover, the present temporary direction
126 from WHO on clinical management of COVID-19 patients recommends against corticosteroid
127 use if not prescribed for another reason. A study conducted at Wuhan Union Hospital
128 retrospectively reviewed forty-six severe COVID-19 pneumonia hospitalized patients for the use
129 of intravenous methylprednisolone (dose 1-2mg/kg/d for 5-7 days in 26 patients) in 26 of them
130 and the other 20 as control. Data of this study indicate that early, low-dose, and short-term use of
131 corticosteroids in patients with severe COVID-19 was correlated with the quick improvement of
132 various symptoms and absorption of lung focus [23]. In another study, COVID-19 patients
133 treated with a corticosteroid had adverse clinical symptoms, further aberrations on chest CT, and
134 an elevated inflammation index. Their data indicates that corticosteroid use could not stimulate
135 virus clearance time, length of hospital stay, or overall duration of symptoms persistence in mild
136 COVID-19 patients [24]. Studies have also revealed that corticosteroid treatment in patients

137 with SARS-CoV, MERS-CoV, and SARS-CoV-2, infections had delayed virus clearance and did
138 not significantly improve survival rate, decrease hospitalization time or rate of ICU admission
139 and/or requirement of mechanical ventilation [25].

140 To make evidence-based recommendations for clinicians about the use of corticosteroids in
141 COVID-19 patients require systematic summaries and meta-analysis of the available evidence.
142 Therefore, the contentious results of corticosteroid use in SARS, MERS, influenza pneumonia
143 patients lead us to conduct a systematic review and meta-analysis of all observational,
144 retrospective cohort, and randomized control studies that have compared mortality, secondary
145 infection, ICU stays, and hospital stay of patients who received corticosteroid treatment with the
146 patients who did not. We aimed to recognize the safety and efficacy of corticosteroids as well as
147 their role in clinical outcomes in SARS, MARS, influenza, and COVID-19 patients and also
148 aimed to find out differences in the outcome of different types of studies such as retrospective
149 cohort studies (RCS) and randomized control trials (RCT).

150 **2. Methods**

151 *2.1 Articles search strategies*

152 A literature search was performed in PubMed, Scopus, Cochrane Central Register of Controlled
153 Trials (CENTRAL), Medline, Google Scholar, and Web of Science records using keywords such
154 as: “corticosteroid” or “viral infection” or “patients” or “control study”. No limitation on
155 language, publication type, and location of the word in the article (title, abstract and main text)
156 was used. Our search consisted of articles from 1980 to September 2020. References from
157 similar review articles and selected articles were also checked for matching articles with our
158 selection criteria. We have used PRISMA 2009 checklist for systematic reviews and meta-

159 analysis (www.prisma-statement.org) [26] and available in supplementary data (Suppl. Table
160 ST1).

161 *2.2 Criteria for inclusion and exclusion of articles*

162 Articles were selected for this meta-analysis based on the following inclusion criteria i) patients
163 with respiratory viral infections in each study were treated with corticosteroid ii) study had
164 corticosteroid treatment group and control group (placebo-treated or untreated/matched) iii)
165 study had primary outcome data on mortality, and any of the secondary outcomes such as
166 secondary infection rate, length of ICU stay, length of hospital stay, duration of mechanical
167 ventilation, and number patients in mechanical ventilation. Studies on non-respiratory viral
168 infections, non-English articles, reviews, case study and articles that didn't have full texts were
169 excluded from this analysis.

170 *2.3 Article selection*

171 Every search was grouped and assigned to all the authors to primarily select articles. Next, those
172 selected articles were reassigned to different authors to make a final selection based on our
173 inclusion and exclusion criteria. Titles of selected articles from all of the authors were then copy-
174 pasted into a shared google sheet that was conditionally formatted for matching to avoid
175 duplications. The corresponding author then checked all the selected articles again to confirm
176 inclusion and exclusion criteria match.

177 *2.4 Data extraction*

178 Selected articles were grouped and assigned to all the authors to extract data and put into a
179 google sheet that only the corresponding author had access to. Next, those groups of articles
180 were reassigned to a different author to extract data and record in a separate google sheet. Two
181 sheets were then matched, and any discrepancies were resolved by group meetings via Zoom.

182 Authors were asked to extract information on authors, title, year of publication, number of
183 patient in the treatment arm, number of patient in the control arm, a corticosteroid used, placebo-
184 control or not, type of study, the mortality rate (control/corticosteroid), secondary infection rate
185 (bacterial), secondary infection rate (viral), male/female (% of the total patient), male/female (%
186 of control/corticosteroid group), the mean age of the total patient, mean age of the dead patient,
187 length of hospital stay, length of ICU stay, dead patients underlying health conditions,
188 comorbidities of patients, name of viral infection, length of mechanical ventilation, Viral/RNA
189 clearance time/viral shedding duration, and the median daily dosage of corticosteroid. For any
190 unavailable data in the article during extraction, authors from that article were contacted by
191 emails to see if those data were available.

192 *2.5 Quality assessment*

193 The risk of bias quality of each of the selected studies was individually evaluated by two authors
194 according to the Newcastle-Ottawa Scale for comparative observational studies and
195 nonrandomized trials and the Cochrane Risk of Bias tool for RCTs [27,28]. Disputes related to
196 quality at any point were settled through zoom meetings with the other authors until the
197 agreement was achieved.

198 *2.6 Statistical Analysis*

199 All statistical analysis was performed by using statistical software STATA 13 [29]. The
200 hypothesis was tested using the Mann-Whitney U test. Z statistic and P-value <0.05 were used to
201 test the significance. All the results of the meta-analysis are displayed in the forest plot.
202 Frequencies and proportions are used to report binary variables. On the other hand, mean and
203 standard deviation are used to report continuous variables. Chi-square statistics are used to test
204 statistical heterogeneity. A random-effects model meta-analysis is performed under the

205 appearance of statistical heterogeneity. The derSimonian-Laird estimator is used to estimating
206 between-study variance (τ^2) in a random-effects model. For binary data, we have calculated risk
207 ratio (RR) as a relative effect along with a 95% confidence interval (CI). On the other hand, the
208 standard mean difference (SMD) is calculated as a relative effect for continuous data along with
209 95% CI. We have conducted subgroup analysis based on different types of viruses. A funnel plot
210 is used to check the publication bias and Egger's test of the intercept is used to quantify the
211 asymmetry of the funnel plot and to perform a statistical test.

212 **3. Results**

213 Our search initially identified 2365 records, of which 1344 records were from PubMed, 450 from
214 Cochrane, 101 from Medline, 241 from Scopus, 130 from Web of science, and 100 (first ten
215 pages) from Google scholar. After screening and reading through the title, abstract, and main
216 text, we discarded 1835 studies due to not fulfilling our selection criteria. Twenty-four studies
217 finally satisfied our exclusion and inclusion criteria and were used in this analysis. Further
218 details of the exclusion and inclusion of articles are shown in figure 1.

219 *3.1 Description of the selected studies*

220 All 24 of our selected articles compared outcomes of corticosteroid with the control group and
221 our primary outcome mortality was recorded in all 24 studies [13,30,39–48,31,49–52,32–38].
222 Length of hospital stay (days) was analyzed in 3 studies [13,48,50], secondary infection rate was
223 recorded in 12 studies [32,37,50,51,42–49], length of mechanical ventilation was recorded in 5
224 studies [39,42,49–51], number of patients in mechanical ventilation (MV) was presented in 14
225 studies [13,31,48,50,51,33,34,38,41,42,45–47], length of ICU stay (days) was reported in 6
226 studies [13,43,48–51]. Twenty-three articles included patients with the respiratory viral infection
227 and one article included patients with acute respiratory distress syndrome. Of the 23 respiratory

228 viral infection articles, eight were H1N1, one H7N9, one influenza, one SARS, one MERS, and
229 eleven SARS-CoV-2. Detailed characteristics of studies can be found in supplementary table
230 ST1. We have included studies published between 2007 and September 2020. The outcome
231 between corticosteroid and non-corticosteroid of all 24 studies were compared based on
232 mortality. We have included 16633 patients into our final meta-analysis and systematic review
233 from all 24 studies. Among all the patients, about 7634 patients were treated with corticosteroid
234 and the remaining 8999 patients were in the control group. Baseline characteristics of patients in
235 this analysis are shown in supplementary table ST1.

236 *3.2 Statistical heterogeneity*

237 We have found significant heterogeneity in our meta-analysis of effect of corticosteroid on
238 mortality ($I^2=95.7\%$, $P<0.0001$), secondary infection ($I^2=90.6\%$, $P<0.0001$), MV days
239 ($I^2=70.7\%$, $P=0.009$), MV patients ($I^2=96.4\%$, $P<0.0001$), ICU days ($I^2=91.2\%$, $P<0.0001$),
240 hospital days ($I^2=80.3\%$, $P=0.006$).

241 *3.3 Overall Mortality*

242 First, we combined all the studies and analyzed them as a whole although it is obvious that these
243 viral diseases are different in their pathology and may not react the same but just to understand
244 from an overall point of view. We found that the mortality rate for the patients who received
245 corticosteroids was not significantly higher than that of patients who did not receive
246 corticosteroids (RR: 1.23 (CI: 0.91, 1.65), $Z = 1.35$, $P = 0.176$) (Figure 2). Next, we analyzed
247 them based on viral types and we found that subgroup analysis based on viral types shows
248 differential results (Figure 3). Patients with MERS-CoV, H7N9 viral types favored control over
249 corticosteroid ($Z=3.03$, $P=0.002$ and $Z= 3.05$, $P=0.002$ respectively) and SARS study favored

250 corticosteroid but had just one study, so the results were not very robust. Similar to the overall
251 mortality, H1N1 and SARS-CoV-2 studies showed that the mortality of patients who received
252 corticosteroids was not significantly higher than that of patients who did not receive
253 corticosteroids (Figure 3). On the flip side, different types of SARS-CoV-2 studies showed
254 different outcomes. Retrospective cohort studies leaned towards control over corticosteroids but
255 did not show statistically significant differences in mortality ($Z=1.14$, $P=0.256$), whereas RCT
256 ($Z=2.84$, $P=0.005$) and retrospective controlled cohort ($Z=2.16$, $P=0.031$) studies showed
257 significantly lower mortality when corticosteroids were used (Figure 4).

258 *3.4 Secondary infection*

259 Next, we analyzed if immunosuppressive corticosteroid treatment increases secondary infection
260 rates. Secondary infection, length of hospital stays, and mortality are closely related. On the one
261 hand, secondary infection can increase mortality and length of hospital and ICU stay; on the
262 other hand, the length of hospital stay can increase secondary infection chances. We found that
263 the secondary infection rate for the patients who received corticosteroid is significantly higher
264 than the patients who did not receive corticosteroid (RR: 1.55 (CI: 1.05, 2.28), $Z=2.20$,
265 $P=0.028$) as shown in Figure 5. Similar results were also obtained from a subgroup analysis of
266 patients with H1N1 viral type (RR: 1.58 (CI: 1.01, 2.46), $Z=2.0$, $P=0.045$). Patients with SARS
267 and H7N9 viral types found no significant corticosteroid effect on the secondary infection
268 (Figure 5). Two SARS-CoV-2 studies included data on secondary infection, one of them is RCT
269 [32] and the other is RCS [37]. Interestingly, similar to the mortality data RCT favored
270 corticosteroid but RCS favored control (Figure 5).

271 *3.5 Number of patients in mechanical ventilation*

272 We were intrigued to find out how many patients were in mechanical ventilation (MV) in the
273 corticosteroid treatment group. We found that the number of patients in mechanical ventilation
274 was significantly higher in the corticosteroid group (RR: 1.59 (CI: 1.27, 1.99), $Z=4.10$, $P <$
275 0.0001) as shown in figure 6. Subgroup analysis of patients with H1N1 ($Z=2.39$, $p=0.017$),
276 SARS-CoV-2 ($Z=2.43$, $p=0.015$), and MERS-CoV ($Z=4.04$, $p<0.0001$) also showed us a similar
277 effect of corticosteroid (Figure 6), but patients with H7N9 infection showed no significance
278 ($p=0.058$).

279 *3.6 Length of mechanical ventilation, hospital stay, and ICU stay*

280 If corticosteroid use is associated with prolonged stay in a hospital and a higher number of
281 patients in mechanical ventilation, it might affect the length of mechanical ventilation
282 requirement also. As shown in Suppl. figure S1, our analysis has revealed that the length of
283 mechanical ventilation (days) was significantly higher in patients who received corticosteroid
284 (SMD: 0.18 (CI: 0.02, 0.33), $Z=2.26$, $P=0.024$). All patients were affected by the H1N1 virus.

285 We then analyzed three studies that had data for hospital stays to see if corticosteroid use
286 increases patients' hospital stay. As shown in Suppl. figure S2, length of hospital stay (days) was
287 significantly higher for the corticosteroid group (SMD: 0.58 (CI: 0.22, 0.94), $Z=3.16$, $P=0.002$).
288 Subgroup analysis of patients with MERS-CoV and H1N1 showed similar results (Suppl. figure
289 S3).

290 Next, we analyzed the length of ICU stay of patients receiving corticosteroids. We found that the
291 length of ICU stay in days was significantly higher for patients who received corticosteroids
292 (SMD: 0.48 (CI: 0.17, 0.79), $Z=3.07$, $P=0.002$). (Suppl. figure S4). Similar results were observed

293 from a subgroup analysis of patients with H1N1 and MERS-CoV viral infections (Suppl. figure
294 S5).

295 *3.7 Risk of bias assessment*

296 We have used funnel plot analysis of selected articles to check publication bias and found that
297 the P-value of Egger's test is not significant ($P > 0.09$), which suggests that there is no evidence
298 of publication bias (Suppl. figure S6). In our selected studies risk of selection bias was
299 unavoidable for the studies that were not randomized control trials. The risk of bias identified in
300 the 24 included studies is shown in (Suppl. Table ST2 and Suppl. Table ST3). NOS scores of our
301 selected retrospective cohort and observational studies varied from 6 to 9, suggesting that the
302 quality of our selected studies was high [28]. Nevertheless, most selected studies had
303 considerable comparability bias because we could not adjust for disease severity, and patients
304 with higher disease severity have a tendency to receive corticosteroid treatment.

305 **4. Discussion**

306 This meta-analysis and systematic review included 19 cohort studies and 5 RCTs, with low to
307 high risk of bias, which addressed the association between corticosteroid use and mortality as
308 primary outcome and length of hospital stay, length of ICU stay, length of mechanical
309 ventilation, number of patients required mechanical ventilation, and rate of secondary infection,
310 as a secondary outcome with SRAS-CoV-2, SARS, MERS, and Influenza. The available data
311 suggested that corticosteroid therapy was not significantly associated with lower mortality rate
312 when compared using different virus types and study types but was associated with lower
313 mortality rate when low bias, gold-standard RCTs were analyzed.

314 The use of corticosteroids suppresses systemic inflammation [8]. Following infection with
315 Influenza virus, SARS-CoV, SARS-CoV-2, and MERS-CoV acute respiratory distress and
316 acute lung injury are characterized by uncontrolled local and systemic inflammation [19,53–55].
317 The systemic injury is caused by an extreme host innate response with inflated migration of
318 neutrophils, macrophages, and pro-inflammatory cytokines, promoting typical exudative edema
319 and fibrosis which lead to diffuse alveolar damage, acute necrotizing bronchiolitis with mostly
320 neutrophilic inflammation, and severe alveolar hemorrhage [56,57]. During these diseases, the
321 clinical administration of corticosteroids inhibits immune reactions by suppressing inflammatory
322 responses, inhibiting the migration of inflammatory cells from the systemic circulation to tissues
323 by the suppression of the production of pro-inflammatory cytokines and chemokines, reducing
324 leukocyte trafficking, and preventing immune reactions mediated by T-lymphocytes and B-
325 lymphocytes [48,49,56,58–60]. Immune suppression occurs by the administration of
326 corticosteroid before the inflammatory reaction reaches to deleterious position might even delay
327 viral clearance, lead to extended viremia, and delayed viral RNA clearance, ultimately leading to
328 an increased rate of mortality [61,62]. By applying marginal structural Cox proportional hazards
329 modeling, one of our included studies showed that corticosteroid treatment was correlated with a
330 substantial delay in MERS-CoV RNA clearance (aHR, 0.35; 95% CI, 0.17–0.72; P=0.005) [13]
331 while another study has shown corticosteroids use in patients were associated with lower levels
332 of procalcitonin (0.5 vs 0.7 ng/mL, P=0.02) [51]. On the other hand, the inflammatory response
333 against some respiratory viral infection reaches to point where inflammation-mediated collateral
334 damage becomes more detrimental to the host than the harm caused by the virus itself.
335 Observational and cohort studies prior to the COVID-19 pandemic found a negative effect of
336 corticosteroid use as we have also shown in this meta-analysis. After the pandemic, clinicians

337 stated to use corticosteroid as an immunosuppressive drug to mitigate the cytokine storm but
338 again most of the cohort studies showed higher mortality in the corticosteroid use. Then,
339 randomized control trials were implemented and showed a beneficial effect of corticosteroid use.
340 Because results from RCTs are robust that the cohort studies, it is now evident that cohorts'
341 studies had patient selection and other biases. In this analysis we clearly show how outcome of a
342 drug treatment may vary depending on different diseases/pathogeneses and even on the study
343 types within same disease/pathogenesis.

344 In this meta-analysis, we have found that most of the studies including one RCT [37] (except one
345 RCT [32]) that had data on secondary infection showed that the corticosteroids group was prone
346 to develop secondary infection probably due to the immunosuppressive effect of the drug. One of
347 our included studies revealed that the subjects, who received corticosteroids, had an elevated rate
348 of immunosuppression (46% vs. 32%, $P=0.03$) led to higher secondary bacterial pneumonia
349 cases (57% vs. 22%, $P<0.001$) [50]. Besides, the increased rate of secondary infection due to
350 prolonged ICU stay has also been revealed by another study [63]. Then Again, corticosteroids
351 immune suppression might lead to developing critical illness [64]. One of our included studies
352 has shown that the rate of shock was 43% vs 30% in the corticosteroid group vs the control
353 group [50]. Moreover, corticosteroids treatment increased the need for invasive mechanical
354 ventilation rate to 85% from 51% in the control group [50]. Analysis from the studies before the
355 COVID-19 pandemic showed significant higher secondary infection for the corticosteroid group
356 ($Z=2.2$, $p=0.028$) but two RCT of COVID-19 studies had differential data and could not generate
357 any significance between treatment and control group suggests that more and more RCT studies
358 are needed to reach a conclusion.

359 Moreover, studies before the COVID-19 pandemic (data from SARS, MERS, H1N1) showed
360 that patients treated with corticosteroids had a significantly higher hospital stay, ICU stay, and
361 length of mechanical ventilation. In addition, these patients were more vulnerable to
362 superinfection, such as secondary bacterial pneumonia (57% vs. 22%, $P < 0.001$) or invasive
363 pulmonary fungal infection, and aggravation of underlying conditions, which led them to stay in
364 ICU for longer periods than the control (no-corticosteroid) group [50]. Furthermore, another
365 study exhibited that the clinical administration of corticosteroids deferred the initiation of
366 blocking the viral neuraminidases by neuraminidase inhibitors, with longer ICU stay in patients
367 who did not receive neuraminidase inhibitors within 5 days of illness [65]. None of the RCTs of
368 SARS-CoV-2 had data on hospital stay, ICU stay, and length of mechanical ventilation and due
369 to the selection bias of cohort studies it is now apparent that RCTs are required to get a robust
370 conclusion on these parameters.

371 Regardless of these outcomes, our study has some limitations. First, the strength of the
372 conclusion made by the studies before the COVID-19 pandemic is not so strong because there
373 was only one RCT study in our analysis, all studies that we include in this review are
374 observational studies having many lurking variables. Now that RCTs showed a beneficial effect
375 of corticosteroid, the deleterious effect of it from the cohort studies becomes questionable.
376 Second, we could not separate patients who obtained corticosteroids for underlying disease (e.g.,
377 COPD). We also could not perform subgroup analysis based on doses of steroid received, early
378 or late steroid use, or other factors. Data on dose, duration, timing, types, and rationales of
379 corticosteroid administration and the timing and duration of antiviral therapy were very
380 insufficient. Before starting this review one of the goals was to see what happens if corticosteroid
381 is applied after cytokine storm vs before cytokine storm but due to data limitation, it was not

382 possible to analyze and opens a new avenue to investigate in the future. Third, the baseline
383 criteria of the patients can control outcomes and differences among the studies included in our
384 analysis. For example, an association had been observed between fewer secondary infections and
385 younger age and fewer underlying diseases.

386 **Conclusion**

387 Current meta-analysis supports the use of corticosteroids to treat critically ill patients with
388 COVID-19, because of the strength of the RCTs that shows that the administration of systemic
389 corticosteroids was associated with lower all-cause mortality compared with usual care or
390 placebo.

391 Our analysis also points out that outcome of particular drug treatments for different diseases with
392 comparable pathogenesis may not be similar and for robust outcome data, RCTs are sometimes
393 required.

394 **Abbreviations**

395 RCT- Randomized Control Trial

396 RCS- Retrospective Cohort Study

397 SARS- Severe acute respiratory syndrome

398 MERS- Middle East Respiratory Syndrome

399 SARS-CoV-2- Severe Acute Respiratory Syndrome Coronavirus 2

400 H1N1- Hemagglutinin (H) and Neuraminidase (N)

401 **Declaration of Conflicting Interests**

402 The Author(s) declare(s) that there is no conflict of interest

403 **Funding**

404 The author(s) disclosed that this research received no specific grant from any funding agency in

405 the public, commercial, or not-for-profit sectors.

406 **Supplementary Material**

407 Supplementary material is available for this article online.

408 **Data availability**

409 The data will be made available upon request.

410 **Ethical statement**

411 This work did not require ethical approval as it does not involve any human or animal

412 experiment.

413 **References**

- 414 [1] J.P. Mizgerd, Lung infection--a public health priority., *PLoS Med.* 3 (2006) e76.
415 <https://doi.org/10.1371/journal.pmed.0030076>.
- 416 [2] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu,
417 A novel coronavirus from patients with pneumonia in China, 2019, *N. Engl. J. Med.*
418 (2020).
- 419 [3] T.P. van Staa, H.G. Leufkens, L. Abenhaim, B. Begaud, B. Zhang, C. Cooper, Use of oral
420 corticosteroids in the United Kingdom., *QJM.* 93 (2000) 105–111.
421 <https://doi.org/10.1093/qjmed/93.2.105>.
- 422 [4] T. Rhen, J.A. Cidlowski, Antiinflammatory action of glucocorticoids--new mechanisms
423 for old drugs., *N. Engl. J. Med.* 353 (2005) 1711–1723.
424 <https://doi.org/10.1056/NEJMra050541>.
- 425 [5] H. Schäcke, W.D. Döcke, K. Asadullah, Mechanisms involved in the side effects of
426 glucocorticoids., *Pharmacol. Ther.* 96 (2002) 23–43. [https://doi.org/10.1016/s0163-](https://doi.org/10.1016/s0163-7258(02)00297-8)
427 [7258\(02\)00297-8](https://doi.org/10.1016/s0163-7258(02)00297-8).
- 428 [6] D.W. Cain, J.A. Cidlowski, Immune regulation by glucocorticoids, *Nat. Rev. Immunol.* 17
429 (2017) 233–247. <https://doi.org/10.1038/nri.2017.1>.
- 430 [7] W.W. Chatham, R.P. Kimberly, Treatment of lupus with corticosteroids, *Lupus.* 10 (2001)
431 140–147.
- 432 [8] C. Monton, S. Ewig, A. Torres, M. El□Ebiary, X. Filella, A. Rano, A. Xaubet, Role of
433 glucocorticoids on inflammatory response in nonimmunosuppressed patients with
434 pneumonia: a pilot study, *Eur. Respir. J.* 14 (1999) 218–220.
- 435 [9] C.A. Meier, Mechanisms of immunosuppression by glucocorticoids, *Eur. J. Endocrinol.*

- 436 134 (1996) 50.
- 437 [10] J.-W. Yang, L.-C. Fan, X.-Y. Miao, B. Mao, M.-H. Li, H.-W. Lu, S. Liang, J.-F. Xu,
438 Corticosteroids for the treatment of human infection with influenza virus: a systematic
439 review and meta-analysis, *Clin. Microbiol. Infect.* 21 (2015) 956–963.
- 440 [11] A.M. Quispe-Laime, J.D. Bracco, P.A. Barberio, C.G. Campagne, V.E. Rolfo, R.
441 Umberger, G.U. Meduri, H1N1 influenza A virus-associated acute lung injury: response
442 to combination oseltamivir and prolonged corticosteroid treatment, *Intensive Care Med.*
443 36 (2010) 33–41.
- 444 [12] A. Torres, O. Sibila, M. Ferrer, E. Polverino, R. Menendez, J. Mensa, A. Gabarrús, J.
445 Sellarés, M.I. Restrepo, A. Anzueto, Effect of corticosteroids on treatment failure among
446 hospitalized patients with severe community-acquired pneumonia and high inflammatory
447 response: a randomized clinical trial, *Jama.* 313 (2015) 677–686.
- 448 [13] Y.M. Arabi, Y. Mandourah, F. Al-Hameed, A.A. Sindi, G.A. Almekhlafi, M.A. Hussein,
449 J. Jose, R. Pinto, A. Al-Omari, A. Kharaba, Corticosteroid therapy for critically ill patients
450 with Middle East respiratory syndrome, *Am. J. Respir. Crit. Care Med.* 197 (2018) 757–
451 767.
- 452 [14] Worldometers, COVID-19 CORONAVIRUS PANDEMIC, (2021).
453 <https://www.worldometers.info/coronavirus/> (accessed March 3, 2021).
- 454 [15] H. Ritchie, E. Ortiz-Ospina, D. Beltekian, E. Mathieu, J. Hasell, B. Macdonald, C.
455 Giattino, M. Roser, Statistics and Research, Coronavirus (COVID-19) Vaccinations,
456 (2021). <https://ourworldindata.org/covid-vaccinations> (accessed March 3, 2021).
- 457 [16] B. Russell, C. Moss, G. George, A. Santaolalla, A. Cope, S. Papa, M. Van Hemelrijck,
458 Associations between immune-suppressive and stimulating drugs and novel COVID-19-a

- 459 systematic review of current evidence., *Ecancermedalscience*. 14 (2020) 1022.
460 <https://doi.org/10.3332/ecancer.2020.1022>.
- 461 [17] B. Russell, C. Moss, A. Rigg, M. Van Hemelrijck, COVID-19 and treatment with
462 NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?,
463 *Ecancermedalscience*. 14 (2020).
- 464 [18] J.M. Sanders, M.L. Monogue, T.Z. Jodlowski, J.B. Cutrell, Pharmacologic treatments for
465 coronavirus disease 2019 (COVID-19): a review, *Jama*. 323 (2020) 1824–1836.
- 466 [19] N.L.-S. Tang, P.K.-S. Chan, C.-K. Wong, K.-F. To, A.K.-L. Wu, Y.-M. Sung, D.S.-C.
467 Hui, J.J.-Y. Sung, C.W.-K. Lam, Early enhanced expression of interferon-inducible
468 protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute
469 respiratory syndrome, *Clin. Chem*. 51 (2005) 2333–2340.
- 470 [20] L.J. Stockman, R. Bellamy, P. Garner, SARS: systematic review of treatment effects,
471 *PLoS Med*. 3 (2006) e343.
- 472 [21] Z.A. Memish, S. Perlman, M.D. Van Kerkhove, A. Zumla, Middle East respiratory
473 syndrome, *Lancet*. (2020).
- 474 [22] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z.
475 Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L.
476 Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of
477 patients infected with 2019 novel coronavirus in Wuhan, China, *Lancet*. 395 (2020) 497–
478 506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 479 [23] Y. Wang, W. Jiang, Q. He, C. Wang, B. Wang, P. Zhou, N. Dong, Q. Tong, Early, low-
480 dose and short-term application of corticosteroid treatment in patients with severe
481 COVID-19 pneumonia: single-center experience from Wuhan, China, *MedRxiv*. (2020)

- 482 2020.03.06.20032342. <https://doi.org/10.1101/2020.03.06.20032342>.
- 483 [24] L. Zha, S. Li, L. Pan, B. Tefsen, Y. Li, N. French, L. Chen, G. Yang, E. V Villanueva,
484 Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19), *Med. J.*
485 *Aust.* 212 (2020) 416–420. <https://doi.org/10.5694/mja2.50577>.
- 486 [25] H. Li, C. Chen, F. Hu, J. Wang, Q. Zhao, R.P. Gale, Y. Liang, Impact of corticosteroid
487 therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV
488 infection: a systematic review and meta-analysis, *Leukemia*. 34 (2020) 1503–1511.
489 <https://doi.org/10.1038/s41375-020-0848-3>.
- 490 [26] A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P.A. Ioannidis, M.
491 Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting
492 systematic reviews and meta-analyses of studies that evaluate health care interventions:
493 explanation and elaboration, *J. Clin. Epidemiol.* 62 (2009) e1–e34.
- 494 [27] J.P.T. Higgins, D.G. Altman, P.C. Gøtzsche, P. Juni, D. Moher, A.D. Oxman, J. Savović,
495 K.F. Schulz, L. Weeks, J.A.C. Sterne, The Cochrane Collaboration’s tool for assessing
496 risk of bias in randomised trials, *Bmj*. 343 (2011) d5928.
- 497 [28] A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the
498 quality of nonrandomized studies in meta-analyses, *Eur. J. Epidemiol.* 25 (2010) 603–605.
- 499 [29] L.P. StataCorp, *Stata 13*, Coll. Stn. StataCorp LP. (2014).
- 500 [30] C.M.P. Jeronimo, M.E.L. Farias, F.F.A. Val, V.S. Sampaio, M.A.A. Alexandre, G.C.
501 Melo, I.P. Safe, M.G.S. Borba, R.L. Abreu-Netto, A.B.S. Maciel, Methylprednisolone as
502 adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised,
503 double-blind, phase IIb, placebo-controlled trial, (2020).
- 504 [31] P. Horby, M. Mafham, L. Linsell, J.L. Bell, N. Staplin, J.R. Emberson, M. Wiselka, A.

- 505 Ustianowski, E. Elmahi, B. Prudon, Effect of Hydroxychloroquine in Hospitalized
506 Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled
507 trial., *MedRxiv*. (2020).
- 508 [32] B.M. Tomazini, I.S. Maia, A.B. Cavalcanti, O. Berwanger, R.G. Rosa, V.C. Veiga, A.
509 Avezum, R.D. Lopes, F.R. Bueno, M.V.A.O. Silva, Effect of dexamethasone on days
510 alive and ventilator-free in patients with moderate or severe acute respiratory distress
511 syndrome and COVID-19: the CoDEX randomized clinical trial, *Jama*. 324 (2020) 1307–
512 1316.
- 513 [33] P.-F. Dequin, N. Heming, F. Meziani, G. Plantefève, G. Voiriot, J. Badié, B. François, C.
514 Aubron, J.-D. Ricard, S. Ehrmann, Effect of hydrocortisone on 21-day mortality or
515 respiratory support among critically ill patients with COVID-19: a randomized clinical
516 trial, *Jama*. 324 (2020) 1298–1306.
- 517 [34] Q. Ma, D. Qi, X.Y. Deng, G.D. Yuan, W.G. Tian, Y. Cui, X.F. Yan, D.X. Wang,
518 Corticosteroid therapy for patients with severe novel Coronavirus disease 2019, *Eur Rev*
519 *Med Pharmacol Sci*. 24 (2020) 8194–8201.
- 520 [35] Q. Li, W. Li, Y. Jin, W. Xu, C. Huang, L. Li, Y. Huang, Q. Fu, L. Chen, Efficacy
521 evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-
522 severe COVID-19 pneumonia: a retrospective cohort study, *Infect. Dis. Ther*. 9 (2020)
523 823–836.
- 524 [36] A. Fernández-Cruz, B. Ruiz-Antorán, A. Muñoz-Gómez, A. Sancho-López, P. Mills-
525 Sánchez, G.A. Centeno-Soto, S. Blanco-Alonso, L. Javaloyes-Garachana, A. Galán-
526 Gómez, Á. Valencia-Alijo, A retrospective controlled cohort study of the impact of
527 glucocorticoid treatment in SARS-CoV-2 infection mortality, *Antimicrob. Agents*

- 528 Chemother. 64 (2020).
- 529 [37] Z. Liu, X. Li, G. Fan, F. Zhou, Y. Wang, L. Huang, J. Yu, L. Yang, L. Shang, K. Xie,
530 Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19,
531 Clin. Microbiol. Infect. 27 (2021) 112–117.
- 532 [38] G. Hong, M. Patel, J. Tusha, P. Giri, L. Al-janabi, R.K. Adusumilli, B. Schmidt, S.
533 Kumar, CORTICOSTEROID TREATMENT IN PATIENTS WITH SEVERE COVID-19
534 PNEUMONIA, Chest. 158 (2020) A599.
- 535 [39] E. Diaz, I. Martin-Loeches, L. Canadell, L. Vidaur, D. Suarez, L. Socias, A. Estella, B.G.
536 Rueda, J.E. Guerrero, M. Valverdú-Vidal, Corticosteroid therapy in patients with primary
537 viral pneumonia due to pandemic (H1N1) 2009 influenza, J. Infect. 64 (2012) 311–318.
- 538 [40] J. Villar, C. Ferrando, D. Martínez, A. Ambrós, T. Muñoz, J.A. Soler, G. Aguilar, F. Alba,
539 E. González-Higueras, L.A. Conesa, Dexamethasone treatment for the acute respiratory
540 distress syndrome: a multicentre, randomised controlled trial, Lancet Respir. Med. 8
541 (2020) 267–276.
- 542 [41] X. Lu, T. Chen, Y. Wang, J. Wang, F. Yan, Adjuvant corticosteroid therapy for critically
543 ill patients with COVID-19, Crit. Care. 24 (2020) 1–4.
- 544 [42] J.W. Delaney, R. Pinto, J. Long, F. Lamontagne, N.K. Adhikari, A. Kumar, J.C. Marshall,
545 D.J. Cook, P. Jouvett, N.D. Ferguson, The influence of corticosteroid treatment on the
546 outcome of influenza A (H1N1pdm09)-related critical illness, Crit. Care. 20 (2016) 75.
- 547 [43] I. Martin-Loeches, T. Lisboa, A. Rhodes, R.P. Moreno, E. Silva, C. Sprung, J.D. Chiche,
548 D. Barahona, M. Villabon, C. Balasini, Use of early corticosteroid therapy on ICU
549 admission in patients affected by severe pandemic (H1N1) v influenza A infection,
550 Intensive Care Med. 37 (2011) 272–283.

- 551 [44] L.Y.-C. Yam, A.C.-W. Lau, F.Y.-L. Lai, E. Shung, J. Chan, V. Wong, H.K.H.A.S.C.G.
552 (HASCOG, Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong,
553 *J. Infect.* 54 (2007) 28–39.
- 554 [45] B. Cao, H. Gao, B. Zhou, X. Deng, C. Hu, C. Deng, H. Lu, Y. Li, J. Gan, J. Liu, Adjuvant
555 corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia, *Crit. Care*
556 *Med.* 44 (2016) e318–e328.
- 557 [46] H. Li, S. Yang, L. Gu, Y. Zhang, X. Yan, Z. Liang, W. Zhang, H. Jia, W. Chen, M. Liu,
558 Effect of low to moderate dose corticosteroids on mortality of hospitalized adolescents
559 and adults with influenza A (H1N1) pdm09 viral pneumonia, *Influenza Other Respi.*
560 *Viruses.* 11 (2017) 345–354.
- 561 [47] A.A. Boudreault, H. Xie, W. Leisenring, J. Englund, L. Corey, M. Boeckh, Impact of
562 corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell
563 transplant patients infected with influenza virus, *Biol. Blood Marrow Transplant.* 17
564 (2011) 979–986.
- 565 [48] R. Linko, V. Pettilä, E. Ruokonen, T. Varpula, S. Karlsson, J. Tenhunen, M. Reinikainen,
566 K. Saarinen, J. Perttilä, I. Parviainen, Corticosteroid therapy in intensive care unit patients
567 with PCR confirmed influenza A (H1N1) infection in Finland, *Acta Anaesthesiol.*
568 *Scand.* 55 (2011) 971–979.
- 569 [49] C. Brun-Buisson, J.-C.M. Richard, A. Mercat, A.C.M. Thiébaud, L. Brochard, Early
570 corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress
571 syndrome, *Am. J. Respir. Crit. Care Med.* 183 (2011) 1200–1206.
- 572 [50] S.-H. Kim, S.-B. Hong, S.-C. Yun, W.-I. Choi, J.-J. Ahn, Y.J. Lee, H.-B. Lee, C.-M. Lim,
573 Y. Koh, Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1

- 574 2009 infection: analytic strategy using propensity scores, *Am. J. Respir. Crit. Care Med.*
575 183 (2011) 1207–1214.
- 576 [51] G. Moreno, A. Rodríguez, L.F. Reyes, J. Gomez, J. Sole-Violan, E. Díaz, M. Bodí, S.
577 Trefler, J. Guardiola, J.C. Yébenes, Corticosteroid treatment in critically ill patients with
578 severe influenza pneumonia: a propensity score matching study, *Intensive Care Med.* 44
579 (2018) 1470–1482.
- 580 [52] D.C. Angus, L. Derde, F. Al-Beidh, D. Annane, Y. Arabi, A. Beane, W. van Bentum-
581 Puijk, L. Berry, Z. Bhimani, M. Bonten, Effect of hydrocortisone on mortality and organ
582 support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid
583 domain randomized clinical trial, *Jama.* 324 (2020) 1317–1329.
- 584 [53] R. Cornejo, O. Llanos, C. Fernández, J.C. Díaz, G. Cardemil, J. Salguero, C. Luengo, E.
585 Tobar, C. Romero, L.R. Gálvez, Organizing pneumonia in patients with severe respiratory
586 failure due to novel A (H1N1) influenza, *Case Reports.* 2010 (2010) bcr0220102708.
- 587 [54] N. Hagau, A. Slavcovici, D.N. Gongnanu, S. Oltean, D.S. Dirzu, E.S. Brezozski, M.
588 Maxim, C. Ciuce, M. Mlesnite, R.L. Gavrus, Clinical aspects and cytokine response in
589 severe H1N1 influenza A virus infection, *Crit. Care.* 14 (2010) R203.
- 590 [55] C. Ramsey, A. Kumar, H1N1: viral pneumonia as a cause of acute respiratory distress
591 syndrome, *Curr. Opin. Crit. Care.* 17 (2011) 64–71.
- 592 [56] D. Annane, Pro: the illegitimate crusade against corticosteroids for severe H1N1
593 pneumonia, *Am. J. Respir. Crit. Care Med.* 183 (2011) 1125–1126.
- 594 [57] Y.M. Arabi, H.H. Balkhy, F.G. Hayden, A. Bouchama, T. Luke, J.K. Baillie, A. Al-
595 Omari, A.H. Hajeer, M. Senga, M.R. Denison, Middle East respiratory syndrome, *N.*
596 *Engl. J. Med.* 376 (2017) 584–594.

- 597 [58] M. Confalonieri, R. Urbino, A. Potena, M. Piattella, P. Parigi, G. Puccio, R. Della Porta,
598 C. Giorgio, F. Blasi, R. Umberger, Hydrocortisone infusion for severe community-
599 acquired pneumonia: a preliminary randomized study, *Am. J. Respir. Crit. Care Med.* 171
600 (2005) 242–248.
- 601 [59] F. Ariani, K. Liu, Z. Jing, J. Qu, Glucocorticosteroid in treatment of severe pneumonia,
602 *Mediators Inflamm.* 2013 (2013).
- 603 [60] K. Han, H. Ma, X. An, Y. Su, J. Chen, Z. Lian, J. Zhao, B.-P. Zhu, R.E. Fontaine, Z.
604 Feng, Early use of glucocorticoids was a risk factor for critical disease and death from
605 pH1N1 infection, *Clin. Infect. Dis.* 53 (2011) 326–333.
- 606 [61] S.K. Kasiakou, G.J. Sermaides, A. Michalopoulos, E.S. Soteriades, M.E. Falagas,
607 Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis
608 of randomised controlled trials, *Lancet Infect. Dis.* 5 (2005) 581–589.
- 609 [62] N. Lee, K.C.A. Chan, D.S. Hui, E.K.O. Ng, A. Wu, R.W.K. Chiu, V.W.S. Wong, P.K.S.
610 Chan, K.T. Wong, E. Wong, Effects of early corticosteroid treatment on plasma SARS-
611 associated Coronavirus RNA concentrations in adult patients, *J. Clin. Virol.* 31 (2004)
612 304–309.
- 613 [63] M. Rahmqvist, A. Samuelsson, S. Bastami, H. Rutberg, Direct health care costs and length
614 of hospital stay related to health care-acquired infections in adult patients based on point
615 prevalence measurements, *Am. J. Infect. Control.* 44 (2016) 500–506.
- 616 [64] V.F. Panoulas, K.M.J. Douglas, A. Stavropoulos-Kalinoglou, G.S. Metsios, P.
617 Nightingale, M.D. Kita, M.S. Elisaf, G.D. Kitas, Long-term exposure to medium-dose
618 glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis,
619 *Rheumatology.* 47 (2008) 72–75.

620 [65] N. Lee, Y.-S. Leo, B. Cao, P.K.S. Chan, W.M. Kyaw, T.M. Uyeki, W.W.S. Tam, C.S.K.
621 Cheung, I.M.H. Yung, H. Li, Neuraminidase inhibitors, superinfection and corticosteroids
622 affect survival of influenza patients, *Eur. Respir. J.* 45 (2015) 1642–1652.
623
624

625 **Figure legends**

626 **Figure 1.** Schematic diagram of the article selection process.

627 **Figure 2.** Effect of corticosteroid on mortality ($Z=1.35$, $P=0.176$, RR: Risk Ratio, horizontal line
628 express 95% CI, Diamond represents overall estimate from the meta-analysis, squares represent
629 effect size for each study).

630 **Figure 3.** Subgroup analysis of the effect of corticosteroid on mortality of patients with SARS,
631 H1N1, H7N9, MERS-Cov, and SARS-CoV-2 infection. RR: Risk Ratio, horizontal line express
632 95% CI, Diamond represents overall estimate from the meta-analysis, squares represent effect
633 size for each study.

634 **Figure 4.** Subgroup analysis based on study type of SARS-CoV-2. RCT: Randomized control
635 trial, RR: Risk Ratio, horizontal line express 95% CI, Diamond represents overall estimate from
636 the meta-analysis, squares represent effect size for each study.

637 **Figure 5.** Subgroup analysis of the effect of corticosteroid on the rate of secondary infection for
638 patients with SARS, H1N1, H7N9, and SARS-CoV-2 infection. (RR: Risk Ratio, horizontal line
639 express 95% CI, Diamond represents overall estimate from the meta-analysis, squares represent
640 effect size for each study).

641 **Figure 6.** Subgroup analysis of the effect of corticosteroid on the number of patients receiving
642 Mechanical Ventilation for H1N1, H7N9, MERS-Cov, and SARS-CoV-2 viral infections (RR:
643 Risk Ratio, horizontal line express 95% CI, Diamond represent overall estimate from the meta-
644 analysis, squares represent effect size for each study).

645




Figure 1




Figure 2





Figure 3



NOTE: Weights are from random effects analysis

.0139

1

72.1

Favours Corticosteroid

Favours Control

Figure 4




Figure 5




Figure 6